Biomarkers in Bladder Cancer Surveillance by Sugeeta, Sukumar S. et al.
REVIEW
published: 28 September 2021
doi: 10.3389/fsurg.2021.735868
Frontiers in Surgery | www.frontiersin.org 1 September 2021 | Volume 8 | Article 735868
Edited by:
Daniele Castellani,





Hong Kong SAR, China
Peter Ka-Fung Chiu,
The Chinese University of
Hong Kong, China
Bogdan Geavlete,






This article was submitted to
Genitourinary Surgery,
a section of the journal
Frontiers in Surgery
Received: 03 July 2021
Accepted: 25 August 2021
Published: 28 September 2021
Citation:
Sugeeta SS, Sharma A, Ng K,
Nayak A and Vasdev N (2021)
Biomarkers in Bladder Cancer
Surveillance. Front. Surg. 8:735868.
doi: 10.3389/fsurg.2021.735868
Biomarkers in Bladder Cancer
Surveillance
Sukumar S. Sugeeta 1, Anand Sharma 1, Kenrick Ng 1, Arvind Nayak 2 and Nikhil Vasdev 2,3*
1Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom, 2Department of Urology and
Surgery, Lister Hospital, East and North Herts NHS Trust, Stevenage, United Kingdom, 3 School of Life and Medical
Sciences, University of Hertfordshire, Hatfield, United Kingdom
Aim: This is a narrative review with an aim to summarise and describe urinary biomarkers
in the surveillance of non-muscle-invasive bladder cancer (NMIBC). It provides a
summary of FDA-approved protein biomarkers along with emerging ones which utilise
genetic, epigenetic and exosomal markers. We discuss the current limitations of the
available assays.
Background: Current guidelines advice a combination of cystoscopy, imaging,and urine
cytology in diagnosis and surveillance. Although cytology has a high specificity, it is limited
by low sensitivity particularly in low grade tumours. There are six FDA-approved urinary
assays for diagnosis and surveillance of bladder cancer. They have shown to improve
sensitivity and specificity to be used alongside cytology and cystoscopy but have a lower
specificity in comparison to cytology and false positives often occur in benign conditions.
Recent developments in laboratory techniques has allowed for use of markers which are
RNA-, DNA-based as well as extracellular vesicles in the past decade.
Methods: Using the PubMed/Medline search engines as well as Google Scholar, we
performed an online search using the terms “bladder cancer,” “non-muscle invasive
bladder cancer,” and “urine biomarkers” with filter for articles in English published up to
May 2021. Systematic reviews and original data of clinical trials or observational studies
which contributed to the development of the biomarkers were collated.
Results: Biomarkers identified were divided into FDA-approved molecular biomarkers,
protein biomarkers and gene-related biomarker with a table summarising the findings
of each marker with the most relevant studies. The studies conducted were mainly
retrospective. Due to the early stages of development, only a few prospective studies
have been done for more recently developed biomarkers and limited meta-analyses are
available.Therefore a detailed evaluation of these markers are still required to decide on
their clinical use.
Conclusion: Advancements of analytical methods in BC has driven the research
towards non-invasive liquid-based biomarkers in adjunct to urine cytology. Further large
prospective studies are required to determine its feasibility in a clinical setting as they
are not effective when used in isolation as they have their limitation. With the ongoing
pandemic, other than reduction in costs and increased accuracy, the need for biomarkers
to cope with delay in cystoscopies in diagnosis and surveillance is crucial. Thus clinical
trials with direct comparison is required to improve patient care.
Keywords: biomarker, bladder cancer, surveillance, non-muscular invasive bladder cancer, cancer screening
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INTRODUCTION
Bladder cancer accounts for 90–95% of urothelial cancers.
It is the eight most common cancer in women and fourth
most common cancer in men (1). Most cases present with
non-muscle invasive bladder cancer (NMIBC) and at early
stages this carries a favourable prognosis. However, NMIBC
accounts for 75% of cases and has a high recurrence rate of
80% in high-risk lesions and up to 50% in low risk. The 5
year survival rate is 94% if detected early and therefore early
detection is imperative as intervention drastically influences
overall survival (2).
Currently, bladder cystoscopy in combination with imaging
of the upper urinary tract along with voided urine cytology as
part of surveillance. NICE guidelines recommend cystoscopy
to be done every 3 months for the first 2 years then every
6 months for the next 2 years then once a year thereafter.
Cystoscopy is associated with complications such as a urinary
tract infection, haematuria, pain. The utilisation of both imaging
and cystoscopy is not effective in detecting smaller lesions. Urine
cytology remains the most widely used non-invasive method for
both diagnosis and surveillance of BC. Studies have shown a
high specificity of 86% but this is limited by its low sensitivity
of 48% as there is subjective nature when grading urothelial
carcinoma on urine samples resulting in poor inter-observer
variability (3). Although routinely used as the standard of truth
for assessment of diagnostic accuracy, it is well-recognised that
traditional cystoscopy with use of white light can lead to missing
lesions that are present but not visible. New technologies exist to
improve tumour visualisation. A recent study compared the use
of blue light flexible cystoscopy with hexaminolevulinate (HAL,
Hexvix R©, Photocure ASA) with white light flexible cystoscopy
for the detection of bladder cancer during surveillance, finding
that 20.6 % (95% CI 11.5–32.7, p < 0.0001) of patients with
recurrent cancer was seen only with blue light (4). The fact
that a significant proportion of recurrences are missed under
white light cystoscopy should be taken into consideration when
assessing the sensitivity of new markers.
Urinary biomarkers play an important role in the future of
precisionmedicine given the limitations of the current modalities
being used given the specificity and sensitivity and need for
invasive procedures to allow for surveillance. There is also a
significant impact due to costs involved to healthcare services
given the frequency and reliance on cystoscopy at present. This
has led to the development of several non-invasive biomarkers
which are now FDA approved. This is now particularly relevant
with regard to low and intermediate risk patients who have had
cystoscopies deferred with the ongoing pandemic. UroFollow is
a multi-centre prospective trial exploring follow up using urine
biomarkers in comparison to standard of care to explore if
non-invasive methods are sufficient or patients with low grade
or pTa G1–G2 BC (5). In addition to diagnostic accuracy,
biomarkers need to be reproducible tests, affordable and easily
implementable. This review’s aim is to summarise biomarkers
which have been identified for use in BC surveillance which are




The United States Food and Drug Administration (FDA)
have currently approved 6 urinary assays to use alongside
cystoscopy for diagnosis and surveillance. These include BTA
stat (Polymedco), BTA TRAK (Polymedco), NMP22 enzyme
linked immune-sorbent assay (ELISA) (Matritech), NMP22
BladderChek Test (Alere), uCyt (Scimedx) and UroVysion
(Abbott Molecular).
NMP22
Nuclear matrix proteins are non chromatin structures which
play several roles from DNA replication to gene expression and
contributes to the infrastructure of the cell nucleus. During
replication in healthy cells, NMP22 regulates the distribution of
chromatin to daughter cells and this is normally at low levels. In
urothelial tumours, levels of NMPs are high due to cell turnover
from tumour apoptosis. NMP22 is one of them and it is the
most investigated as an assay in both diagnosis and recurrence
of bladder cancer.
Two modes of detection were FDA approved for both
diagnosis and surveillance. NMP22 were initially detected with
quantitative ELISA in a laboratory where cut-off values were
utilised. The second was a qualitative point-of-care test, the
NMP22 BladderChek where monoclonal antibodies are used to
detect raised NMP22 levels in BC.
In 2015, Chou et al. had done a meta-analysis identifying
qualitative NMP22 which has a sensitivity of 69% and specificity
of 77% and qualitative NMP22 has 83% in specificity and 70% in
sensitivity (6). A meta-analysis by Wang et al. in 2017 showed a
pooled sensitivity from of 56% and specificity of 88% for bladder
cancer detection from 19 studies (7). However the sensitivity
was low when tumour stage and grade were considered with
sensitivity increasing steadily with stage of 13.68, 29.49, and
74.03% for Ta to T1 and >T2, respectively. It was also found to
have a better diagnostic performance in the Asian population.
NMP22 measures the cell turnover that occurs with surface
shedding from bladder tumour. This process occurs in benign
conditions such as inflammation, infection, bladders stones and
haematuria thus resulting in false-positive results.
Bladder Tumour Antigen (BTA) Assays
BTA tests detect human complement factor-H related protein in
the urine which is produced by our bodies to protect cells from
complement activation. It has an almost identical structure to
the complement factor-H related protein produced by bladder
cancer cells. There are two forms of BTA assays: (1) BTA Stat test:
a “point-of-care (POC)” immunochromatographic assay which
utilises five drops of urine to deliver a result within 5min, and (2)
BTA-TRAK test: standard quantitative ELISA measurement of
the antigen. The FDA have approved them both for surveillance
in BC in conjunction with cystoscopy only.
A meta-analysis conducted reviewing 13 studies identified
specificity and sensitivity of BTA stat test to be 67 and 75%,
respectively (8). Although BTA stat had shown higher sensitivity
that urine cytology, the latter had better specificity. Chou et al.
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reviewed 22 studies identifying the sensitivity of BTA STAT was
64 % and specificity was 77%. For BTA-TRAK, four studies were
evaluated and had similar results with a sensitivity of 65% and
specificity was 74% (6). Similarly to other biomarkers, sensitivity
had a positive correlation with increasing tumour grade of
the BC.
Overall, the sensitivity and specificity of BTA Stat test ranges
from 56 to 83% and 64 to 86% and with specificity up to 93% in
individuals with benign conditions (9–12), and with BTA TRAK
this ranges from 62 to 76% and 51 to 98% (13). Glas et al. carried
out a meta-analysis and results of the bivariate analysis showed a
sensitivity and specificity of cytology, BTA-Stat and BTA TRAK
to be the following 55 and 94%; 70, 75, and 66%, and 65%,
respectively (14). Given their lower specificities and similar issue
of false positive results in benign conditions such as previous
intravesical therapy, kidney stones, infection and presence of
ureteric stents or nephrostomy tubes, theses tests are unable to
replace cytology and can only be used concurrently as part of
surveillance (9, 12, 15, 16).
UroVysion
UroVysion is a molecular test using multicolour fluorescence
in situ hybridisation (FISH) assay to detect aneuploidy of
chromosomes 3, 7, and 17 and loss of the p16 gene at the 9p21
locus which are genetic abnormalities seen in BC. A sample
must have a minimum of 25 cells to be analysed and a positive
test is defined by one of the following: (1) Four or more
morphologically abnormal cells have polysomy of two or more
chromosomes (3, 7, or 17) (2) ≥10 cells with gain of a single
chromosome (3) homozygous deletion of 9p21 in 12 cells (16).
Pooled results from a meta-analysis of 13 studies showed a
specificity of 83% and sensitivity of 72% in comparison to urine
cytology with 96 and 42%, respectively (17). UroVysion showed
the sensitivity and specificity of 75.6 and 84.8%, respectively for
high grade UCC, 40.8 and 87.8%, respectively for lowgrade UCC
(18). Thus it faced a similar challenge to biomarkers in detection
of low grade or low stage tumours (19). However the advantage
of this assay is the absence of benign conditions such as cystitis,
inflammation or haematuria affecting results.
In surveillance, Yoder et al. identified over a period of 29
months that 65% of the cases with positive UroVysion but no
visible lesions developed recurrence on follow-up but this was
not the case for Dimashkieh et al. as where 46% (158 of 343) of
patients who had positive UroVysion tests did not develop UCC
during up to the 3 year follow-up (18, 20). Therefore there is
variability in its clinical utility. There is also evidence to show its
potential in assessing response to intravesical BCG therapy for
NMIBC (21).
Immunocyt/Ucyt + Test
The Immunocyt/Ucyt+ test uses three fluorescent monoclonal
antibodies (M344, LDQ10, and 19A211) which detect
carcinoembryonic antigen and sulphated mucin glycoproteins
on exfoliated urothelial cells in voided urine. Compoj et al.
evaluated 7,244 cases and identified an overall sensitivity of
34.5% for cytology and 68.1% for uCyt+/ImmunoCyt and
97.9% for cytology, 72.3% for uCyt+/ImmunoCyt (22). There
was a positive correlation with higher grade and specificity
along with sensitivity as observed with other biomarkers. A
meta-analysis identified a sensitivity of ImmunoCyt to be 75%
and specificity was 78% and in comparison to NMP22, BTA
and FISH, it had the highest pooled sensitivity (6). A split study
comparing UroVysion, ImmunoCyt and cytology supported this
with Immunocyst being more sensitive in detecting low grade
tumours (23). Further meta-analysis also supported previous
evidence to support the use of Immunocyt in combination with
cytology in surveillance to reduce the frequency of follow up
required in low risk cancers (24).
However, this test involves advanced technical expertise as a
minimum of 500 cells need to be analysed for fluorescence to
provide accurate results and thus there is interobserver variability
and need for high cellularity specimens. It can be affected by
benign conditions such as haematuria albeit not as easily as other
biomarkers above (25).
PROMISING PROTEIN BIOMARKERS
Table 1 summarises potential protein biomarkers which can be
used in BC surveillance highlighting meta-analysis and most
relevant study in the table.
The UK National Health Service (NHS) approved the usage
of ADxBladder in BC detection. Three prospective studies
have been done with only one in the surveillance setting (43).
They reported an overall sensitivity ranging between 45–73%,
specificity between 70–73%, and NPV between 74–100% and
were superior to cytology (47). Given the turnaround time of
2h, it being relatively unaffected by benign conditions such as
inflammation or haematuria and consisting of a single biomarker
identifiable with ELISA which is readily available in labs and
costing only £0.37 per person, this made ADxBladder a viable
option (48). However, in comparison to other biomarkers
identified, it has a low sensitivity and specificity as displayed in
Table 1 and poor performance in detection of low grade tumours.
Of the new protein biomarkers that were introduced in
recent years, URO17 test utilising Keratin 17 (K17) has shown
especially promising results. Babu et al. had identified high
sensitivity and specificity of URO17 of 100% using urine samples
in a retrospective study (44). Interestingly, URO17 is able to
detect both low and high grade cancers in patients presenting
with haematuria, a previously excluded cohort, thus proving its
benefit of use in a surveillance setting as well (45). There is a
specificity of 96 and 92.7% in recurrent and newly diagnosed
patients, respectively (44, 45). Given these outcomes and its
easy adaptation to current equipment used, a larger prospective
study in a surveillance setting would be beneficial in developing
this into a promising protein biomarker test for non-invasive
surveillance of NMIBC (45, 46).
GENE-RELATED BIOMARKERS
Genetic alterations has been explored as another avenue
for detecting bladder cancer in surveillance. To discuss this
further we will divide these into the following groups:





































TABLE 1 | Additional protein biomarkers.
Biomarker Description Method N C SS SP Comment Ref
UBC Detects the presence of
fragments of cytokeratin 8 and
18 in urine
ELISA or immunoradiometric assay 753 1072 64.4 80.3 UBC values higher in high-grade tumours and
able to distinguish from low-grade. Higher
specificity in combination with cytology or
survivin assay
(26–29)
CYFRA21-1 Quantifies soluble fragments of
cytokeratin 19
ELISA 1262 1233 82.0 80.0 Significantly higher levels in patients with
metastatic disease vs. locally invasive unable to
differentiate between histological grades
(30, 31)
BLCA-4 Measures protein components of
the nuclear matrix which are
present in the urothelium of
BC patients
ELISA 1119 total participants 93.0 97 Meta-analysis mainly retrospective studies
showing potential to detect early tumours. No
positive correlation between tumour stage and
levels measured.
(32, 33)
CellDetect Composed of a unique plant
extract which interacts with
malignant cells due to their
increased metabolic activity
Immunostain 84 110 84.0 70.0 Two studies have shown higher sensitivity in
low grade tumours in comparison to urine
cytology (82% vs 59%) and similar specificity
(86 vs 94%) It was also found not be affected
by haematuria.
(34, 35)
Hyaluronic acid HA is a glycosoaminoglycan and
HAse is endoglucosidase
involved in tumour metastases
and breakdown of HA into
fragments for angiogenesis
ELISA and RT-qPCR 918 participants 90.8 82.5 In comparison to BTA stat, UBC and cytology in
two studies shown superior SS and SP. SS and
SP not affected by tumour grade but levels are
not indicative of tumour grade. More studies
required to evaluate this promising marker.
(36–38)
sFas Anti-apoptotic protein released
by BC cells to protect from
anti-tumour activity
ELISA 128 88 51.2 85.9 Lower sensitivity. Higher levels associated with
higher risk of recurrence.
(39–41)
Survivin Overexpression in BC as a
protein which inhibits apoptosis
pathways
Bio-dot test 50 44 82 90 Limited data available in follow up setting or in
comparison to other biomarkers
(42)
MCM5 - ADXBladder Detects MCM5 shed by
replicating BC cells
ELISA 503 patients 51.9 66.4 Findings in prospective study in comparison to
UC with SS 16.9% and SP 98%. Low
sensitivity for low grade tumours. 99% NPV for
high risk NMIBC
(43)
URO17 Detects oncoprotein Keratin 17
involved in the replication of
cancer cells
Immunocyto-chemistry 81 98 97 AUC: 90 Consistently high sensitivity and specificity from
3 independent studies. Good potential as
simple incorporation to existing equipment
(44–46)
N, tumour samples; C, control; SS, sensitivity; SP, specificity; UBC, Urinary bladder cancer; BLCA-4, Human Bladder Cancer-associated Nuclear Matrix Protein4; HA, hyaluronic acid; HAse, hyaluronidase; sFas, soluble Fas; RT-qPCR,
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DNA methylation markers, histone tail modifications, miRNA
biomarkers, microsatellite analysis and multi-gene panels.
Table 2 summarises detection of genetic alterations to utilise
as biomarkers listing themost relevant study accounting for those
with the largest patient groups and most representative of the
target group.
DNA Methylation Markers
Epigenetic alterations are part of the carcinogenesis. DNA
hypermethylation of the CpG islands play a role in the promoter
regions of tumour-suppressor genes. This mediates silencing
of the affiliated gene which is a known phenomenon in BC.
The hyper or hypomethylation of these genes can be detected
in tumour cells that are shed into urine and aid diagnosis of
BC. This has been reviewed in both primary and recurrent
tumours. Bosschieter et al. evaluated 42 studies and identified 8
with high sensitivity and specificity with varying methodologies
and heterogenous patient groups (66). Studies with promising
results, had no independent validation data and Costa et al.
with 94% specificity and 90% sensitivity did not report on
tumour grade or stage (67). This is relevant as similarly to other
reported biomarkers, results will vary with disease spectrum. As
shown in Table 2 section DNA Methylation Markers studies in
recurrence are listed but these are mainly small retrospective
case-control studies (50). Beuker at al, as shown inTable 2, used a
combination of this technique along with DNAmutation analysis
with FGFR3 and TERT mutation analysis to improve detection
rates showed similar results as increased sensitivity in high grade
tumour cells likely due to increased shedding of BC cells (49).
There is an insufficient amount of data due to variability in
methodology, patient groups and gene panel selection. Studies
have used it in combination with DNA mutation analysis.
Histone Tail Modifications
Other than epigenetic changes described above, another
manifestation of this is histone lysine methylation (HxKy).
Histone modifications help regulate numerous cell mechanisms
such as chromosome condensation, DNA repair and
transcription. The site and degree of histone methylation
determines the transcriptional activity. H3K9, as mentioned in
Table 2 section Histone Tail Modifications are associated with
repressed transcription. Other potential histone modications
identified are H3K4 and H3K20 methylation which were
decreased in BC compared to normal patients and global
H4K20me3 levels were predictive for bladder cancer-specific
survival (68).
miRNA Biomarkers
Micro RNAs (miRNA) are short noncoding RNAs that
regulate process post-transcriptionally and dysregulation leads
to carcinogenesis. The aberrant expression of miRNA has led
to its potential use as a biomarker. It can present in bodily
fluids as they are protected by RNAse degradation because they
are excreted as membrane-protected free circulating miRNAs or
in extracellular vesicles (EVs) such as exosomes (69). Initially
identification was done using qtPCR but now rapid profiling is
done using microassays and miRNA sequencing (56).
Studies listed in Table 2 section miRNA Biomarkers are those
with sensitivities of more than 80%. Multiple miRNA diagnostic
assays had better sensitivity than single miRNA assays. Chen et al.
carried out a meta-analysis 30 studies with 1019 BC patients and
690 controls identifying a pool sensitivity and specificity of 80
and 74%, respectively (70). The AUC for NMIBC was 0.84 and
0.76 for MIBC suggesting higher diagnostic ability in NMIBC
patients. Another meta-analysis by Shi et al. evaluated 1,556 cases
and 1,347 controls from 31 studies with a pooled specificity and
sensitivity of 72 and 76%, respectively (71).
Most studies compared a heterogenous group of BC patients
with controls. Study which explored the recurrence setting in
both NMIBC and MIBC using miR-145 and miR-200a. This
identified a sensitivity of 78% and specificity of 61% in NMIBC
patients where lower levels of miR-145 associated with higher
grade and lower levels of miR-200a independently predicted
recurrence (72). Prospective trials in BC surveillance are required
to validate the clinical applicability of this biomarker.
Multi-Gene Panels
Several assays detectingmRNA biomarkers have been conducted.
Table 2 section Multi-Gene Panels summarises them. CxBladder
has been extensively studied and has variations which include:
(1) Cxbladder R© Detect to detect bladder cancer in hematuria
patients with a sensitivity of 82% and specificity of 85% (62).
(2) Cxbladder R© Triage which is used in hematuria patients to
rule out BC with a sensitivity of 95% and negative predictive
value of 97% (73). (3) Cxbladder R© Monitor as a complement to
surveillance. It has been compared with urine cytology, NMP22
BladderChek and NMP22 ELISA with a superior SS and SP
of 91/96 vs. 22/87%, 11/87 and 26/86 % (74). Koya et al.
implemented CxBladder Monitor (CxBM) into local guidelines
whereby low risk patients had alternate annual CxBM and
cystoscopy therearfter (75). They found that 77.8% of patients
were safely managed by only one cystoscopy every 2 years,
reducing the total number of annual cystoscopies by 39%.
This was reflected in a real world data analysis identifying
this advantage of CxBM in clinical practice to have driven its
increased utility (76).
Other Possible Gene-Related Biomarkers
Microsatellite analysis (MSA) through PCR targets highly
pleomorphic short tandem repeats (STR) which occur in cancer
cells with loss of heterozygosity (LOH) causing microsatellite
instability. This occurs because of epigenetic silencing or
inactivation of the mismatch repair gene which play an integral
part in the proliferation of cancer cells. The most common
LOH is in chromosome nine but this is also seen to occur in
chromosome 4, 8, 11, and 17p (77–80). In comparison to urine
cytology, sensitivity was 97 vs. 79% with 95–100% in low grade
tumours in a small study of 34 cancer patients with 21 cancer-
free subjects (81). A prospective study of 228 patients undergoing
BC surveillance had a specificity and sensitivity of 58 and 74%,
respectively (82). A further prospective study of 91 patients
evaluatingMSA in combination with cytology had a sensitivity of
72% in G1–2 and 96% in G3. They found using LOH analysis to
improve specificity and all recurrence cases were identified (83).





































TABLE 2 | Gene-related biomarkers.
Biomarker Description M N C SS SP Comment Ref
4.1 FGFR3, TERT and
OTX1
Combination of DNA methylation







Large prospective study identified
lower sensitivity in follow up HG and
LG patients in comparison to primary





Detects 4 hotspot mutations in
FGFR3 in combination with DNA
methylation levels
qMS-PCR 157 63 58 Combination with methylation shows
sensitivity of 94% in low grade and





Detecting changes in DNA
methylation in BC cells shed in urine
90 86 89 Tumour recurrence predicted in 80%
of patients, superior to cytology (35%)
and cystoscopy (15%)
(51)
APC _ a, TERT _ a,
TERT _ b, and EDNRB
MS-MLPA 49 60 72 55 All HG recurrent tumours including






HTFs help regulate cell processes
which are fundamental to DNA repair.





113 61 N/A H3K9 and H3K27 levels correlate
with invasiveness of BC along with
grade and pT stage of NMIBC,







Analysis of 364 different miRs was
analysed in 16 urine samples to
identify a 6 gene signature
miRNA assay 130‘ 112 AUC 88.3% AUC of 88.0%, 92.9% and 91.0%, for
LGNMIBC, HGNIMBC and MIBC
respectively. Validation sets were
done. Newly diagnosed patients only,









In bold, overexpressed in BC and in
italics, they were under expressed.
miRNA assay 27 10 85 87 2 step model predicts progression
and cancer specific survival in NMIBC







Panel of 12 miRNAs profiled and
identified set of 6. Validation study
included.
RTq-PCR 81 21 88 48 AUC 0.85 in predicting recurrence in
surveillance setting. Better







Seven miRNA identified to have
significantly higher levels in the cancer
group
RTq-PCR 85 45 88 78 No validation study. Highest sensitivity




A panel of 46 miRNAs monitored in
an independent cohort of 121
subjects identifying 25-target panel

























































































TABLE 2 | Continued
Biomarker Description M N C SS SP Comment Ref
4.4 Xpert Bladder Detects expression levels of 5 mRNA
expression of genes (CRH, IGF2,
UPK1B,
ANXA10, and ABL1)
LDA 239 - 74 80 Prospective study. Higher SN and
NPV compared with cytology and
UroVysion with NPV of 98% in HG
disease
(59)
AssureMDX Mutation analysis in FGFR3, TERT,
and HRAS
genes and methylation analysis in
OTX1,
ONECUT2, and TWIST1 genes
SNaPshot®
+ MS-PCR
74 80 97 83 Follow up validation study showed SS
of 93 and SP of 86. AUC higher in




CxBladder IGFBP5, HOXA13, MDK, and CDK1
are associated with carcinogenesis
and the 5th biomarker (CXCR2) is a
marker of inflammation reducing false
positive results
Rt-qPCR 66 417 82 85 97% SS in HG tumours and 69% in
Ta. Greater SS in comparison to urine
cytology and NMP-22
(62)
EpiCheck Blinded, single-arm, prospective
multicenter study using Epicheck (15




353 - 68 88 SS 100%, 40%, 89% in Cis, LG and
HG respectively.
(63)
Uromonitor FGFR3 hotspot and TERT promoter
mutations
Rt-qPCR 122 - 73 73 Addition of KRAS mutation to
UroMonitor V2 kit, increased SS to
100% and specificity to 83.3%
(64)
UroSEEK Mutations in 11 genes or presence of
abnormal number of chromosomes
NGS 496 - 74 72 UroSEEK positivity preceded tumour
recurrence diagnosis by 4 months in
average. However, this is a
retrospective study and prospective
studies needed.
(65)
M, Method; N, number of malignant samples or cancer patients; C, control; SS, sensitivity; SP, specificity; Ref, reference; LG, low grade; HG, high grade; Cis, Carcinoma in situ; qMS-PCR, quantitative methylation specific-polymerase
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Overall, this test has good sensitivity but difficult to incorporate
into present laboratories due to its complexity. Larger prospective




Exosomes are vesicles secreted by cells which mediate
extracellular communication by transmitting proteins, lipids,
miRNA, mRNA and long non-coding RNAs (lncRNA).
Extracellular vesicles in BC cells carry a vast number of proteins
which is utilised in angiogenesis and cell migration thus aiding
further tumour progression which can be utilised as markers
but possible novel therapeutic targets (84). Different analytical
methods have identified various proteins and miRNAs in this
rich extracellular environment. A small study isolated EV using
microchip ELISA and found highly elevated EV levels in BC
patients compared to controls (85). Profiling of proteomes in
exosomes identified a correlation with tumour grade and the
ability to predict recurrences with 1-antitrypsin and histone
H2B1 exosome proteins (86). In another study, urinary EVs were
isolated and deregulated miRNAs were identified as potential
biomarkers, in particular, miR-375 for high-grade bladder cancer
while miR-146a for low-grade patients (87).
EVs are promising as a source of biomarkers given the diverse
cargoes EVs carry. However, there are several limitations such
as isolation techniques and testing not being standardised and
therefore it is difficult to compare results between groups given
lack of reproducibility. Studies conducted are heterogenous and
small without any validation sets (88). Optimisation of testing
could lead to better EV studies allowing for real EV biomarker
development in a clinical setting and could further inform us
further on tumour biology.
CONCLUSION
This paper has highlighted the various biomarkers in urothelial
cancer and their significance in early diagnosis of bladder cancer.
Whilst it’s important to have biomarkers in NMIBC, differences
in sensitivity and specificity limits their use in the community.
These biomarkers have a significant role in future diagnosis of
bladder cancer, and future studies will guide clinicians in using
the most appropriate marker for screening. The advancement in
analytical methods in BC has driven the research towards non-
invasive liquid-based biomarkers in adjunct to urine cytology.
This paper provides evidence that a second modality of screening
tool may be beneficial to use in the diagnostic algorithm for
bladder cancer. Studies identifying its feasibility in a clinical
enviroment is important as they have limitations when used in
isolation. Given this is a narrative review, further evaluation of
these promising markers is required in more depth in terms
of a meta-analysis along with the development of prospective
studies in a surveillance setting. Meta-analyses on the newer
markers have not been conducted as there is variability in
patient cohorts utilised and more studies need to be conducted
to obtain sufficient data. In addition to this, majority of
studies are in a restrospective setting and prospective studies
need to be developed to be able to further evaluate their
clinical feasibility.
The ongoing pandemic has further accentuated the increasing
need and relevance for biomarkers to cope with delay in
cystoscopies in both diagnosis and surveillance. The use of
more sensitive methods to detect true tumour recurrences could
also play a role in assessment of the diagnostic accuracy of
these markers, potentially reducing the number of cystoscopies
for test-negative cases and introducing methods like blue light
cystoscopy for test-positive cases. Further large, prospective
clinical trials incorporating these biomarkers and usage of
newer analytical methods in screening for high-risk patients
and also in disease recurrence in will allow for its use in a
clinical setting.
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